1. Home
  2. PSNL vs SDGR Comparison

PSNL vs SDGR Comparison

Compare PSNL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Personalis Inc.

PSNL

Personalis Inc.

HOLD

Current Price

$6.33

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$11.46

Market Cap

850.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSNL
SDGR
Founded
2011
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
729.1M
850.5M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
PSNL
SDGR
Price
$6.33
$11.46
Analyst Decision
Strong Buy
Buy
Analyst Count
5
8
Target Price
$12.20
$21.13
AVG Volume (30 Days)
1.5M
914.8K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
33.58
45.14
EPS
N/A
N/A
Revenue
$69,648,000.00
$255,869,000.00
Revenue This Year
$15.47
$1.20
Revenue Next Year
$39.24
$4.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.29
52 Week Low
$2.97
$10.95
52 Week High
$11.50
$27.63

Technical Indicators

Market Signals
Indicator
PSNL
SDGR
Relative Strength Index (RSI) 37.27 41.51
Support Level $4.65 $11.03
Resistance Level $9.64 $13.36
Average True Range (ATR) 0.51 0.49
MACD -0.03 0.04
Stochastic Oscillator 13.68 35.02

Price Performance

Historical Comparison
PSNL
SDGR

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Share on Social Networks: